The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomas

Science

Volumn 352, Issue 6288, 2016, Pages

  Quail, Daniela F ^a   Bowman, Robert L ^a   Akkari, Leila ^a,b   Quick, Marsha L ^a   Schuhmacher, Alberto J ^a   Huse, Jason T ^a   Holland, Eric C ^c   Sutton, James C ^d   Joyce, Johanna A ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

^c Fred Hutchinson Cancer Research Center   (United States)

^d NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; AS 1517499; BLZ 945; BUPARLISIB; CD3 ANTIGEN; CD8 ANTIGEN; COLONY STIMULATING FACTOR 1 RECEPTOR; COLONY STIMULATING FACTOR RECEPTOR; INTERLEUKIN 4; LINSITINIB; PHOSPHATIDYLINOSITOL 3 KINASE; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; STAT6 PROTEIN; TRANSCRIPTION FACTOR NFAT; UNCLASSIFIED DRUG; 3-(8-AMINO-1-(2-PHENYLQUINOLIN-7-YL)IMIDAZO(1,5-A)PYRAZIN-3-YL)-1-METHYLCYCLOBUTANOL; 4-(2-(2-HYDROXYCYCLOHEXYLAMINO)BENZOTHIAZOL-6-YLOXY)PYRIDINE-2-CARBOXYLIC ACID METHYLAMIDE; BENZOTHIAZOLE DERIVATIVE; CSF1R PROTEIN, MOUSE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR; IMIDAZOLE DERIVATIVE; PICOLINIC ACID DERIVATIVE; PYRAZINE DERIVATIVE;

CANCER; EXPERIMENTAL STUDY; GENE EXPRESSION; GENETIC ANALYSIS; INHIBITION; INHIBITOR; RODENT; SURVIVAL; TUMOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER MODEL; CANCER PATIENT; CANCER RECURRENCE; CANCER REGRESSION; CANCER RESISTANCE; CONTROLLED STUDY; GLIOBLASTOMA; GLIOMA; HUMAN; HUMAN CELL; MACROPHAGE; MICROGLIA; MOUSE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; TREATMENT OUTCOME; TUMOR MICROENVIRONMENT; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; DRUG RESISTANCE; IMMUNOLOGY; INBRED MOUSE STRAIN; METABOLISM; NEOPLASMS, EXPERIMENTAL; SIGNAL TRANSDUCTION; TUMOR RECURRENCE; UMBILICAL VEIN ENDOTHELIAL CELL;

ANIMALIA; MUS;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZOTHIAZOLES; DRUG RESISTANCE, NEOPLASM; GLIOBLASTOMA; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; IMIDAZOLES; INSULIN-LIKE GROWTH FACTOR I; MACROPHAGES; MICE; MICE, INBRED STRAINS; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, EXPERIMENTAL; NFATC TRANSCRIPTION FACTORS; PHOSPHATIDYLINOSITOL 3-KINASES; PICOLINIC ACIDS; PYRAZINES; RECEPTOR, IGF TYPE 1; RECEPTORS, GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; SIGNAL TRANSDUCTION; STAT6 TRANSCRIPTION FACTOR; TUMOR MICROENVIRONMENT;

EID: 84971538906     PISSN: 00368075     EISSN: 10959203     Source Type: Journal    
DOI: 10.1126/science.aad3018     Document Type: Article

References (78)

1. D. F. Quail, J. A. Joyce, Microenvironmental regulation of tumor progression and metastasis. Nat. Med. 19, 1423-1437 (2013). doi: 10.1038/nm.3394; pmid: 24202395
2. M. R. Junttila, F. J. de Sauvage, Influence of tumour microenvironment heterogeneity on therapeutic response. Nature 501, 346-354 (2013). doi: 10.1038/nature12626; pmid: 24048067
3. R. Stupp et al., Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352, 987-996 (2005). doi: 10.1056/NEJMoa043330; pmid: 15758009
4. Y. Komohara, K. Ohnishi, J. Kuratsu, M. Takeya, Possible involvement of the M2 anti-inflammatory macrophage phenotype in growth of human gliomas. J. Pathol. 216, 15-24 (2008). doi: 10.1002/path.2370; pmid: 18553315
5. L. Bingle, N. J. Brown, C. E. Lewis, The role of tumourassociated macrophages in tumour progression: Implications for new anticancer therapies. J. Pathol. 196, 254-265 (2002). doi: 10.1002/path.1027; pmid: 11857487
6. S. F. Hussain et al., The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses. Neuro-oncol. 8, 261-279 (2006). doi: 10.1215/15228517-2006-008; pmid: 16775224
7. B. Ruffell, L. M. Coussens, Macrophages and therapeutic resistance in cancer. Cancer Cell 27, 462-472 (2015). doi: 10.1016/j.ccell.2015.02.015; pmid: 25858805
8. S. M. Pyonteck et al., CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat. Med. 19, 1264-1272 (2013). doi: 10.1038/nm.3337; pmid: 24056773
9. S. J. Coniglio et al., Microglial stimulation of glioblastoma invasion involves epidermal growth factor receptor (EGFR) and colony stimulating factor 1 receptor (CSF-1R) signaling. Mol. Med. 18, 519-527 (2012). doi: 10.2119/molmed.2011.00217; pmid: 22294205
10. S. Patel, M. R. Player, Colony-stimulating factor-1 receptor inhibitors for the treatment of cancer and inflammatory disease. Curr. Top. Med. Chem. 9, 599-610 (2009). doi: 10.2174/156802609789007327; pmid: 19689368
11. C. H. Ries et al., Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Cancer Cell 25, 846-859 (2014). doi: 10.1016/j.ccr.2014.05.016; pmid: 24898549
12. W. D. Tap et al., Structure-guided blockade of CSF1R kinase in tenosynovial giant-cell tumor. N. Engl. J. Med. 373, 428-437 (2015). doi: 10.1056/NEJMoa1411366; pmid: 26222558
13. D. Hambardzumyan, N. M. Amankulor, K. Y. Helmy, O. J. Becher, E. C. Holland, Modeling adult gliomas using RCAS/t-va technology. Transl. Oncol. 2, 89-95 (2009). doi: 10.1593/tlo.09100; pmid: 19412424
14. S. Hänzelmann, R. Castelo, J. Guinney, GSVA: Gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics 14, 7 (2013). doi: 10.1186/1471-2105-14-7; pmid: 23323831
15. S. M. Brachmann et al., Characterization of the mechanism of action of the pan class I PI3K inhibitor NVP-BKM120 across a broad range of concentrations. Mol. Cancer Ther. 11, 1747-1757 (2012). doi: 10.1158/1535-7163.MCT-11-1021; pmid: 22653967
16. C. W. Brennan et al., The somatic genomic landscape of glioblastoma. Cell 155, 462-477 (2013). doi: 10.1016/j.cell.2013.09.034; pmid: 24120142
17. P. Therasse et al., New guidelines to evaluate the response to treatment in solid tumors. J. Natl. Cancer Inst. 92, 205-216 (2000). doi: 10.1093/jnci/92.3.205; pmid: 10655437
18. J. E. Burda, M. V. Sofroniew, Reactive gliosis and the multicellular response to CNS damage and disease. Neuron 81, 229-248 (2014). doi: 10.1016/j.neuron.2013.12.034; pmid: 24462092
19. E. N. Arwert, E. Hoste, F. M. Watt, Epithelial stem cells, wound healing and cancer. Nat. Rev. Cancer 12, 170-180 (2012). doi: 10.1038/nrc3217; pmid: 22362215
20. F. Ginhoux, J. L. Schultze, P. J. Murray, J. Ochando, S. K. Biswas, New insights into the multidimensional concept of macrophage ontogeny, activation and function. Nat. Immunol. 17, 34-40 (2016). doi: 10.1038/ni.3324; pmid: 26681460
21. R. L. Bowman, J. A. Joyce, Therapeutic targeting of tumorassociated macrophages and microglia in glioblastoma. Immunotherapy 6, 663-666 (2014). doi: 10.2217/imt.14.48; pmid: 25041027
22. G. Locatelli et al., Primary oligodendrocyte death does not elicit anti-CNS immunity. Nat. Neurosci. 15, 543-550 (2012). doi: 10.1038/nn.3062; pmid: 22366759
23. K. Gabrusiewicz et al., Characteristics of the alternative phenotype of microglia/macrophages and its modulation in experimental gliomas. PLOS ONE 6, e23902 (2011). doi: 10.1371/journal.pone.0023902; pmid: 21901144
24. J. D. Sedgwick et al., Isolation and direct characterization of resident microglial cells from the normal and inflamed central nervous system. Proc. Natl. Acad. Sci. U.S.A. 88, 7438-7442 (1991). doi: 10.1073/pnas.88.16.7438; pmid:1651506
25. F. Kratochvill et al., TNF counterbalances the emergence of M2 tumor macrophages. Cell Reports 12, 1902-1914 (2015). doi: 10.1016/j.celrep.2015.08.033; pmid: 26365184
26. S. K. Biswas, A. Mantovani, Macrophage plasticity and interaction with lymphocyte subsets: Cancer as a paradigm. Nat. Immunol. 11, 889-896 (2010). doi: 10.1038/ni.1937; pmid: 20856220
27. R. Ostuni et al., Latent enhancers activated by stimulation in differentiated cells. Cell 152, 157-171 (2013). doi: 10.1016/j.cell.2012.12.018; pmid: 23332752
28. D. M. Mosser, J. P. Edwards, Exploring the full spectrum of macrophage activation. Nat. Rev. Immunol. 8, 958-969 (2008). doi: 10.1038/nri2448; pmid: 19029990
29. A. Mantovani, S. K. Biswas, M. R. Galdiero, A. Sica, M. Locati, Macrophage plasticity and polarization in tissue repair and remodelling. J. Pathol. 229, 176-185 (2013). doi: 10.1002/path.4133; pmid: 23096265
30. B. J. Faler, R. A. Macsata, D. Plummer, L. Mishra, A. N. Sidawy, Transforming growth factor-b and wound healing. Perspect. Vasc. Surg. Endovasc. Ther. 18, 55-62 (2006). doi: 10.1177/153100350601800123; pmid: 16628336
31. J. Silver, J. H. Miller, Regeneration beyond the glial scar. Nat. Rev. Neurosci. 5, 146-156 (2004). doi: 10.1038/nrn1326; pmid: 14735117
32. F. E. Lund, B. A. Garvy, T. D. Randall, D. P. Harris, Regulatory roles for cytokine-producing B cells in infection and autoimmune disease. Curr. Dir. Autoimmun. 8, 25-54 (2005). doi: 10.1159/000082086; pmid: 15564716
33. D. P. Harris et al., Reciprocal regulation of polarized cytokine production by effector B and T cells. Nat. Immunol. 1, 475-482 (2000). doi: 10.1038/82717; pmid: 11101868
34. B. Johansson-Lindbom, C. A. Borrebaeck, Germinal center B cells constitute a predominant physiological source of IL-4: Implication for Th2 development in vivo. J. Immunol. 168, 3165-3172 (2002). doi: 10.4049/jimmunol.168.7.3165; pmid: 11907068
35. O. Butovsky, A. E. Talpalar, K. Ben-Yaakov, M. Schwartz, Activation of microglia by aggregated beta-amyloid or lipopolysaccharide impairs MHC-II expression and renders them cytotoxic whereas IFN-γ and IL-4 render them protective. Mol. Cell. Neurosci. 29, 381-393 (2005). doi: 10.1016/j.mcn.2005.03.005; pmid: 15890528
36. S. J. Forbes, N. Rosenthal, Preparing the ground for tissue regeneration: From mechanism to therapy. Nat. Med. 20, 857-869 (2014). doi: 10.1038/nm.3653; pmid: 25100531
37. M. W. Wynes, D. W. Riches, Induction of macrophage insulin-like growth factor-I expression by the Th2 cytokines IL-4 and IL-13. J. Immunol. 171, 3550-3559 (2003). doi: 10.4049/jimmunol.171.7.3550; pmid: 14500651
38. B. K. Kaspar, J. Lladó, N. Sherkat, J. D. Rothstein, F. H. Gage, Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model. Science 301, 839-842 (2003). doi: 10.1126/science.1086137; pmid: 12907804
39. W. H. Zheng, S. Kar, S. Doré, R. Quirion, Insulin-like growth factor-1 (IGF-1): A neuroprotective trophic factor acting via the Akt kinase pathway. J. Neural Transm. Suppl. 2000, 261-272 (2000).pmid: 11205145
40. S. Dupraz et al., The insulin-like growth factor 1 receptor is essential for axonal regeneration in adult central nervous system neurons. PLOS ONE 8, e54462 (2013). doi: 10.1371/journal.pone.0054462; pmid: 23349896
41. A. M. Fernandez, I. Torres-Alemán, The many faces of insulin-like peptide signalling in the brain. Nat. Rev. Neurosci. 13, 225-239 (2012). doi: 10.1038/nrn3209; pmid: 22430016
42. M. Pollak, Insulin and insulin-like growth factor signalling in neoplasia. Nat. Rev. Cancer 8, 915-928 (2008). doi: 10.1038/nrc2536; pmid: 19029956
43. A. Liberzon et al., The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 1, 417-425 (2015). doi: 10.1016/j.cels.2015.12.004; pmid: 26771021
44. A. Murat et al., Modulation of angiogenic and inflammatory response in glioblastoma by hypoxia. PLOS ONE 4, e5947 (2009). doi: 10.1371/journal.pone.0005947; pmid: 19536297
45. + T helper cell effector functions. Blood 115, 2989-2997 (2010). doi: 10.1182/blood-2009-10-233585; pmid: 20103781
46. N. Butowski et al., Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: An Ivy Foundation Early Phase Clinical Trials Consortium phase II study. Neuro-oncol. 18, 557-564 (2016). doi: 10.1093/neuonc/nov245; pmid: 26449250
47. C. Holohan, S. Van Schaeybroeck, D. B. Longley, P. G. Johnston, Cancer drug resistance: An evolving paradigm. Nat. Rev. Cancer 13, 714-726 (2013). doi: 10.1038/nrc3599; pmid: 24060863
48. M. J. Mulvihill et al., Discovery of OSI-906: A selective and orally efficacious dual inhibitor of the IGF-1 receptor and insulin receptor. Future Med. Chem. 1, 1153-1171 (2009). doi: 10.4155/fmc.09.89; pmid: 21425998
49. M. H. Roehrl et al., Selective inhibition of calcineurin-NFAT signaling by blocking protein-protein interaction with small organic molecules. Proc. Natl. Acad. Sci. U.S.A. 101, 7554-7559 (2004). doi: 10.1073/pnas.0401835101; pmid: 15131267
50. K. Loser et al., FK506 controls CD40L-induced systemic autoimmunity in mice. J. Invest. Dermatol. 126, 1307-1315 (2006). doi: 10.1038/sj.jid.5700185; pmid: 16470176
51. Y. Chiba, M. Todoroki, Y. Nishida, M. Tanabe, M. Misawa, A novel STAT6 inhibitor AS1517499 ameliorates antigen-induced bronchial hypercontractility in mice. Am. J. Respir. Cell Mol. Biol. 41, 516-524 (2009). doi: 10.1165/rcmb.2008-0163OC; pmid: 19202006
52. C. Dai et al., PDGF autocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas and oligoastrocytomas from neural progenitors and astrocytes in vivo. Genes Dev. 15, 1913-1925 (2001). doi: 10.1101/gad.903001; pmid: 11485986
53. E. Tchougounova et al., Loss of Arf causes tumor progression of PDGFB-induced oligodendroglioma. Oncogene 26, 6289-6296 (2007). doi: 10.1038/sj.onc.1210455; pmid: 17438529
54. T. Ozawa et al., Most human non-GCIMP glioblastoma subtypes evolve from a common proneural-like precursor glioma. Cancer Cell 26, 288-300 (2014). doi: 10.1016/j.ccr.2014.06.005; pmid: 25117714
55. M. Squatrito et al., Loss of ATM/Chk2/p53 pathway components accelerates tumor development and contributes to radiation resistance in gliomas. Cancer Cell 18, 619-629 (2010). doi: 10.1016/j.ccr.2010.10.034; pmid: 21156285
56. X. Hu et al., mTOR promotes survival and astrocytic characteristics induced by Pten/AKT signaling in glioblastoma. Neoplasia 7, 356-368 (2005). doi: 10.1593/neo.04595; pmid: 15967113
57. J. T. Huse et al., The PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and facilitates gliomagenesis in vivo. Genes Dev. 23, 1327-1337 (2009). doi: 10.1101/gad.1777409; pmid: 19487573
58. A. H. Shih et al., Dose-dependent effects of platelet-derived growth factor-B on glial tumorigenesis. Cancer Res. 64, 4783-4789 (2004). doi: 10.1158/0008-5472.CAN-03-3831; pmid: 15256447
59. J. B. Jensen, M. Parmar, Strengths and limitations of the neurosphere culture system. Mol. Neurobiol. 34, 153-161 (2006). doi: 10.1385/MN:34:3:153; pmid: 17308349
60. N. J. Szerlip et al., Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response. Proc. Natl. Acad. Sci. U.S.A. 109, 3041-3046 (2012). doi: 10.1073/pnas.1114033109; pmid: 22323597
61. V. Ponomarev et al., A novel triple-modality reporter gene for whole-body fluorescent, bioluminescent, and nuclear noninvasive imaging. Eur. J. Nucl. Med. Mol. Imaging 31, 740-751 (2004). doi: 10.1007/s00259-003-1441-5; pmid: 15014901
62. M. Serrano et al., Role of the INK4a locus in tumor suppression and cell mortality. Cell 85, 27-37 (1996). doi: 10.1016/S0092-8674(00)81079-X; pmid: 8620534
63. D. N. Louis et al., The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 114, 97-109 (2007). doi: 10.1007/s00401-007-0243-4; pmid: 17618441
64. D. C. Allred, J. M. Harvey, M. Berardo, G. M. Clark, Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod. Pathol. 11, 155-168 (1998). pmid: 9504686
65. V. E. Seshan, A. Olshen, DNAcopy: DNA copy number data analysis. R package version 1.44.0.
66. A. Dobin et al., STAR: Ultrafast universal RNA-seq aligner. Bioinformatics 29, 15-21 (2013). doi: 10.1093/bioinformatics/bts635; pmid: 23104886
67. H. Li et al., The Sequence Alignment/Map format and SAMtools. Bioinformatics 25, 2078-2079 (2009). doi: 10.1093/bioinformatics/btp352; pmid: 19505943
68. S. Anders, P. T. Pyl, W. Huber, HTSeq-A Python framework to work with high-throughput sequencing data. Bioinformatics 31, 166-169 (2015). doi: 10.1093/bioinformatics/btu638; pmid: 25260700
69. C. W. Law, Y. Chen, W. Shi, G. K. Smyth, voom: Precision weights unlock linear model analysis tools for RNA-seq read counts. Genome Biol. 15, R29 (2014). doi: 10.1186/gb-2014-15-2-r29; pmid: 24485249
70. G. Dennis Jr. et al., DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol. 4, 3 (2003). doi: 10.1186/gb-2003-4-5-p3 pmid: 12734009
71. A. Subramanian et al., Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. U.S.A. 102, 15545-15550 (2005). doi: 10.1073/pnas.0506580102; pmid: 16199517
72. P. J. Balwierz et al., ISMARA: Automated modeling of genomic signals as a democracy of regulatory motifs. Genome Res. 24, 869-884 (2014). doi: 10.1101/gr.169508.113; pmid: 24515121
73. M. Setty et al., Inferring transcriptional and microRNAmediated regulatory programs in glioblastoma. Mol. Syst. Biol. 8, 605 (2012). doi: 10.1038/msb.2012.37; pmid: 22929615
74. M. Pachkov, I. Erb, N. Molina, E. van Nimwegen, SwissRegulon: A database of genome-wide annotations of regulatory sites. Nucleic Acids Res. 35 (Database), D127-D131 (2007). doi: 10.1093/nar/gkl857; pmid: 17130146
75. J. Friedman, T. Hastie, R. Tibshirani, Regularization paths for generalized linear models via coordinate descent. J. Stat. Softw. 33, 1-22 (2010). doi: 10.18637/jss.v033.i01; pmid: 20808728
76. Y. Zhu, P. Qiu, Y. Ji, TCGA-assembler: Open-source software for retrieving and processing TCGA data. Nat. Methods 11, 599-600 (2014). doi: 10.1038/nmeth.2956; pmid: 24874569
77. H. Wickham, ggplot2: Elegant Graphics for Data Analysis (Springer, 2009).
78. S. Epskamp, A. O. J. Cramer, L. J. Waldorp, V. D. Schmittmann, D. Borsboom, qgraph: Network visualizations of relationships in psychometric data. J. Stat. Softw. 48, 1-18 (2012). doi: 10.18637/jss.v048.i04